IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Patient Enrolment Completed for INSIGHT-003

06 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

17 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

16 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

12 12 2024 08:15:00 提供 Nasdaq GlobeNewswire

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

10 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

14 11 2024 08:15:00 提供 Nasdaq GlobeNewswire

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

14 11 2024 08:00:01 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q1 FY25

29 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

28 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

17 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

10 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

03 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

24 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

18 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

16 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

20 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

14 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep to Participate in Upcoming Investor Conferences

07 8 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q4 FY24

31 7 2024 08:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

22 7 2024 08:00:00 提供 Nasdaq GlobeNewswire